FindTrial
Sign In

Modified FOLFIRINOX

DRUG9 trials

Sponsors

Cancer Institute Hospital, Gifu University Hospital, Emory University, AbbVie, Onconic Therapeutics Inc.

Conditions

Advanced Gastrointestinal, Biliary Tract, and Pancreatic CancersCancer of PancreasCancer of the PancreasLocally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaNeoplasms, PancreaticPancreas CancerPancreas Neoplasms

Phase 1

Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
CompletedNCT01446458
Emory UniversityCancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic +2
Start: 2011-11-30End: 2015-03-31Updated: 2016-03-22
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
TerminatedNCT04807972
AbbViePancreatic Cancer
Start: 2021-05-28End: 2024-03-25Updated: 2025-01-07
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
RecruitingNCT05257993
Onconic Therapeutics Inc.Pancreatic Ductal Adenocarcinoma
Start: 2022-03-30End: 2026-06-30Target: 30Updated: 2025-02-19
Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas
WithdrawnNCT05926206
University of Michigan Rogel Cancer CenterMetastatic Pancreatic Adenocarcinoma
Start: 2023-07-31End: 2027-01-31Updated: 2023-08-02
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
RecruitingNCT06360354
AmgenAdvanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Start: 2024-05-29End: 2029-02-25Target: 350Updated: 2026-03-31

Phase 2

Phase II trial of modified FOLFIRINOX (irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin) in patients with untreated metastatic pancreatic cancer
Active, not recruitingJPRN-UMIN000013301
Cancer Institute Hospitaluntreated metastatic pancreatic cancer
Start: 2014-02-20Target: 65Updated: 2025-07-18
Phase II study of modified FOLFIRINOX as first-line for advanced pancreatic cancer
Active, not recruitingJPRN-UMIN000015376
Gifu University Hospitaladvanced pancreatic cancer
Start: 2014-10-01Target: 28Updated: 2025-07-18
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
RecruitingNCT06048484
Gulam ManjiPancreatic Ductal Adenocarcinoma
Start: 2024-05-10End: 2027-04-01Target: 60Updated: 2026-02-27
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
RecruitingNCT06850623
EXACT Therapeutics ASLocally Advanced Pancreatic Adenocarcinoma
Start: 2025-06-19End: 2027-07-15Target: 25Updated: 2026-04-03

Related Papers

Abstract 7065: Targeting MTAP-deleted/KRAS mutant cancers using RAS inhibitors in combination with AMG 193, an MTA-cooperative PRMT5 inhibitor.
Cancer Research2026-04-03
A phase 2 study to investigate the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX in patients with locally advanced pancreatic cancer.
Journal of Clinical Oncology2026-01-10
Abstract A068: A phase 2 study to investigate the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX in patients with locally advanced pancreatic cancer
Cancer Research2025-09-28
An open-label, dose-finding, phase Ib study to assess the safety, tolerability of nesuparib (JPI-547), a dual inhibitor of PARP/TNKS, in combination with modified FOLFIRINOX (mFOLFIRINOX) and gemcitabine-nab-paclitaxel (GemAbraxane) in patients with locally advanced and metastatic pancreatic cancer.
Journal of Clinical Oncology2025-05-28
AIRPanc: A phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection.
Journal of Clinical Oncology2024-01-20
Abstract CT246: Phase 1b/2 study of giloralimab in combination with modified FOLFIRINOX with or without budigalimab in patients with untreated metastatic pancreatic cancer
Cancer Research2022-06-15
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
2021-02-164 citations
Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial
BMJ Open2020-11-014 citations
Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Journal of Clinical Oncology2016-05-2012 citations